Citations

Showing 10 of 108104 citations.

The fundamentals of sex‐based disparity in liver transplantation: Understanding can lead to change
Singh, Noreen , Watt, Kymberly D. , Bhanji, Rahima A.

Mayo Clinic

Liver Transplantation | March 15, 2022 | Volume: 28 | Issue: 8 | Pages: 1367-1375

10.1002/lt.26456 | PMID 35289056 Get It

Abstract Liver transplantation (LT) is the definitive treatment for end‐stage liver disease. Unfortunately, women are disadvantaged at every stage of the LT process. We conducted a literature review to increase the understanding of this disparity. Hormonal differences, psychological factors, and Model for End‐Stage Liver Disease (MELD) score inequalities are some pretransplantation factors that contribute to this disparity. In the posttransplantation setting, women have differing risk than men in most major outcomes (perioperative complications, rejection, long‐term renal dysfunction, and malignancy) and assessing the two groups together is disadvantageous. Herein, we propose interventions including standardized criteria for LT referral, using an alternate MELD, education for support of women, and motivating women to seek living donors. Understanding sex‐based differences will allow us to improve access, tailor management, and improve overall outcomes for all patients, particularly women.
Associations of the MUC5B promoter variant with timing of interstitial lung disease and rheumatoid arthritis onset
McDermott, Gregory C , Gagne, Staci , Huang, Weixing , Cui, Jing , Prisco, Lauren, Zaccardelli, Alessandra , Kronzer, Vanessa L. , Dellaripa, Paul F. , Doyle, Tracy J. , Sparks, Jeffrey A. , McDermott, Gregory , Cui, Jing , Kronzer, Vanessa L , Sparks, Jeffrey A , Gill, Ritu R. , Byrne, Suzanne , Martin, Lily K. , Moll, Matthew , Cho, Michael H. , Shadick, Nancy A.

Mayo Clinic

Rheumatology | March 15, 2022 | Volume: 61 | Issue: 12 | Pages: 4915-4923

10.1093/rheumatology/keac152 | PMID 35289841 Get It

Abstract Objectives To investigate the associations of the common MUC5B promoter variant with timing of RA-associated interstitial lung disease (RA-ILD) and RA onset. Methods We identified patients with RA meeting 2010 ACR/EULAR criteria and available genotype information in the Mass General Brigham Biobank, a multihospital biospecimen and clinical data collection research study. We determined RA-ILD presence by reviewing all RA patients who had CT imaging, lung biopsy or autopsy results. We determined the dates of RA and RA-ILD diagnoses by manual records review. We examined the associations of the MUC5B promoter variant (G>T at rs35705950) with RA-ILD, RA-ILD occurring before or within 2 years of RA diagnosis and RA diagnosis at age >55 years. We used multivariable logistic regression to estimate odds ratios (ORs) for each outcome by MUC5B promoter variant status, adjusting for potential confounders including genetic ancestry and smoking. Results We identified 1005 RA patients with available genotype data for rs35705950 (mean age 45 years, 79% female, 81% European ancestry). The MUC5B promoter variant was present in 155 (15.4%) and was associated with RA-ILD [multivariable OR 3.34 (95% CI 1.97, 5.60)], RA-ILD before or within 2 years of RA diagnosis [OR 4.01 (95% CI 1.78, 8.80)] and RA onset after age 55 years [OR 1.52 (95% CI 1.08, 2.12)]. Conclusions The common MUC5B promoter variant was associated with RA-ILD onset earlier in the RA disease course and older age of RA onset. These findings suggest that the MUC5B promoter variant may impact RA-ILD risk early in the RA disease course, particularly in patients with older-onset RA.
The Current Knowns and Unknowns of COVID-19 Vaccine-Induced Immunity in Patients With Inflammatory Bowel Disease
Rolak, Stacey , Caldera, Freddy , Caldera, Freddy

Mayo Clinic

American Journal of Gastroenterology | March 15, 2022 | Volume: 117 | Issue: 5 | Pages: 731-732

10.14309/ajg.0000000000001729 | PMID 35288512 Get It

Evidence for machine learning guided early prediction of acute outcomes in the treatment of depressed children and adolescents with antidepressants
Athreya, Arjun P. , Voort, Jennifer L. Vande , Shekunov, Julia , Rackley, Sandra , Leffler, Jarrod M. , McKean, Alastair J. , Romanowicz, Magdalena , Emslie, Graham J. , Mayes, Taryn L. , Trivedi, Madhukar H. , Wang, Liewei , Weinshilboum, Richard M. , Vande Voort, Jennifer L., Rackley, Sandra J, Bobo, William V. , Mayes, Taryn , Kennard, Betsy D. , Weinshilboum, Richard M. , Croarkin, Paul E.

Mayo Clinic

Journal of Child Psychology and Psychiatry | March 15, 2022 | Volume: 63 | Issue: 11 | Pages: 1347-1358

10.1111/jcpp.13580 | PMID 35288932 Get It

Background The treatment of depression in children and adolescents is a substantial public health challenge. This study examined artificial intelligence tools for the prediction of early outcomes in depressed children and adolescents treated with fluoxetine, duloxetine, or placebo. Methods The study samples included training datasets ( N = 271) from patients with major depressive disorder (MDD) treated with fluoxetine and testing datasets from patients with MDD treated with duloxetine ( N = 255) or placebo ( N = 265). Treatment trajectories were generated using probabilistic graphical models (PGMs). Unsupervised machine learning identified specific depressive symptom profiles and related thresholds of improvement during acute treatment. Results Variation in six depressive symptoms (difficulty having fun, social withdrawal, excessive fatigue, irritability, low self‐esteem, and depressed feelings) assessed with the Children’s Depression Rating Scale‐Revised at 4–6 weeks predicted treatment outcomes with fluoxetine at 10–12 weeks with an average accuracy of 73% in the training dataset. The same six symptoms predicted 10–12 week outcomes at 4–6 weeks in (a) duloxetine testing datasets with an average accuracy of 76% and (b) placebo‐treated patients with accuracies of 67%. In placebo‐treated patients, the accuracies of predicting response and remission were similar to antidepressants. Accuracies for predicting nonresponse to placebo treatment were significantly lower than antidepressants. Conclusions PGMs provided clinically meaningful predictions in samples of depressed children and adolescents treated with fluoxetine or duloxetine. Future work should augment PGMs with biological data for refined predictions to guide the selection of pharmacological and psychotherapeutic treatment in children and adolescents with depression.
Polygenic risk score for peripheral artery disease: A tool to refine risk stratification
Kullo, Iftikhar J. , Kullo, Iftikhar J

Mayo Clinic

Vascular Medicine | March 15, 2022 | Volume: 27 | Issue: 3 | Pages: 228-229

10.1177/1358863x221080191 | PMID 35287515 Get It

In Search of Medical Professionalism Research: Preliminary Results from a Review of Widely Read Medical Journals
Isaacson, J. Harry , Ziring, Deborah , Hafferty, Fred, Littleton, Dawn , Frankel, Richard M. , Hafferty, Frederic W. , Kalet, Adina L.

Mayo Clinic

The Permanente Journal | March 15, 2022 | Volume: 25 | Issue: 3 | Pages: 1-7

10.7812/tpp/20.223 | PMID 35348058 Get It

What Is the Brainstem Control of Locomotion?
Ali, Farwa , Benarroch, Eduardo E.

Mayo Clinic

Neurology | March 14, 2022 | Volume: 98 | Issue: 11 | Pages: 446-451

10.1212/wnl.0000000000200108 | PMID 35288473 Get It

Influence of Nonsyndromic Bicoronal Synostosis and Syndromic Influences on Orbit and Periorbital Malformation
Lu, Xiaona , Forte, Antonio J. , Dinis, Jacob , Junn, Alexandra , Alperovich, Michael , Alonso, Nivaldo , Persing, John A. , Forte, Antonio Jorge

Mayo Clinic

Plastic & Reconstructive Surgery | March 14, 2022 | Volume: 149 | Issue: 5 | Pages: 930e-942e

10.1097/prs.0000000000009051 | PMID 35286288 Get It

Background: Oculoorbital disproportion in patients with craniosynostosis has similarities and dissimilarities between syndromic and nonsyndromic cases. The authors hypothesized that these two conditions have specific individual influences as they relate to development of the orbital and periorbital skeletons. Methods: A total of 133 preoperative computed tomography scans (nonsyndromic bicoronal synostosis, n = 38; Apert syndrome bicoronal synostosis subtype, n = 33; Crouzon syndrome bicoronal synostosis subtype, n = 10; controls, n = 52) were included. Craniometric and volumetric analyses related to the orbit and periorbital anatomy were performed. Results: Orbital cavity volume was mildly restricted in nonsyndromic bicoronal synostosis (7 percent, p = 0.147), but more so in Apert and Crouzon syndromes [17 percent (p = 0.002) and 21 percent (p = 0.005), respectively]. The sphenoid side angle in Apert syndrome was wider than when compared to Crouzon syndrome (p = 0.043). The ethmoid side angle in Apert patients, however, was narrower (p = 0.066) than that in Crouzon patients. Maxilla anteroposterior length was more restricted in Apert syndrome than Crouzon syndrome (21 percent, p = 0.003) and nonsyndromic cases (26 percent, p < 0.001). The posterior nasal spine position was retruded in Crouzon syndrome (39 percent, p < 0.001), yet the anterior nasal spine position was similar in Apert and Crouzon syndromes. Conclusions: Orbit and periorbital malformation in syndromic craniosynostosis is likely the combined influence of syndromic influences and premature suture fusion. Apert syndrome expanded the anteriorly contoured lateral orbital wall associated with bicoronal synostosis, whereas Crouzon syndrome had more infraorbital rim retrusion, resulting in more severe exorbitism. Apert syndrome developed maxillary hypoplasia, in addition to the maxillary retrusion, observed in Crouzon syndrome and nonsyndromic bicoronal synostosis patients. CLINICAL QUESTION/LEVEL OF EVIDENCE: Risk, II.
Annals On Call - Are Adrenal Incidentalomas Clinically Important?
Centor, Robert M., Bancos, Irina, Prete, Alessandro, Prete, Alessandro , Prete, Alessandro , Centor, Robert M., Bancos, Irina

Mayo Clinic

Annals of Internal Medicine | March 14, 2022 | Volume: 175 | Issue: 3 | Pages: OC1

10.7326/a21-0007 | PMID 35286824 Get It

Connectomic analysis of unilateral dual-lead thalamic deep brain stimulation for treatment of multiple sclerosis tremor
Patel, Bhavana , Middlebrooks, Erik H. , Hilliard, Justin D. , Foote, Kelly D. , Okun, Michael S. , Okun, Michael S , Middlebrooks, Erik H , Wong, Joshua K. , Almeida, Leonardo

Mayo Clinic

Brain Communications | March 14, 2022 | Volume: 4 | Issue: 2 | Pages: No page available

10.1093/braincomms/fcac063 | PMID 35368612 Get It

Abstract Tremor is a common symptom in multiple sclerosis and can present as a severe postural and action tremor, leading to significant disability. Owing to the diffuse and progressive nature of the disease, it has been challenging to characterize the pathophysiology underlying multiple sclerosis tremor. Deep brain stimulation of the ventralis intermedius and the ventralis oralis posterior thalamic nuclei has been used to treat medically refractory multiple sclerosis tremors with variable results. The aim of this study was to characterize multiple sclerosis tremor at the network level by applying modern connectomic techniques to data from a previously completed single-centre, randomized, single-blind prospective trial of 12 subjects who were treated with unilateral dual-lead (ventralis intermedius + ventralis oralis posterior) thalamic deep brain stimulation. Preoperative T1-weighted MRI and postoperative head CTs were used, along with applied programming settings, to estimate the volume of tissue activated for each patient. The volumes of tissue activated were then used to make voxel-wise and structural connectivity correlations with clinically observed tremor suppression. The volume of the tissue-activated analyses identified the optimal region of stimulation at the ventralis oralis posterior ventralis intermedius border intersecting with the dentato-rubro-thalamic tract. A regression model showed strong connectivity to the supplemental motor area was positively associated with tremor suppression (r = 0.66) in this cohort, whereas connectivity to the primary motor cortex was negatively associated with tremor suppression (r = −0.69), a finding opposite to that seen in ventralis intermedius deep brain stimulation for essential tremor. Comparing the structural connectivity to that of an essential tremor cohort revealed a distinct network that lies anterior to the essential tremor network. Overall, the volumes of tissue activated and connectivity observations converge to suggest that optimal suppression of multiple sclerosis tremor will likely be achieved by directing stimulation more anteriorly toward the ventralis oralis posterior and that a wide field of stimulation synergistically modulating the ventralis oralis posterior and ventralis intermedius nuclei may be more effective than traditional ventralis intermedius deep brain stimulation at suppressing the severe tremors commonly seen in complex tremor syndromes such as multiple sclerosis tremor.